285 related articles for article (PubMed ID: 19414943)
21. Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients.
Sánchez-Escuredo A; Batista F; Cases A; Torregrosa JV
Transplant Proc; 2015; 47(1):73-5. PubMed ID: 25645774
[TBL] [Abstract][Full Text] [Related]
22. Triumph and tragedy: anemia management in chronic kidney disease.
Novak JE; Szczech LA
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
[TBL] [Abstract][Full Text] [Related]
23. Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
Otsuka T; Sakai Y; Yui S; Sukegawa M; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Tsuruoka S
J Nippon Med Sch; 2015; 82(1):21-6. PubMed ID: 25797871
[TBL] [Abstract][Full Text] [Related]
24. [Long-acting erythropoetin efficacy in the treatment of nephrogenic anemia in patients with chronic kidney disease during predialysis stage].
Milovanov IuS; Milovanova LIu
Ter Arkh; 2012; 84(6):48-52. PubMed ID: 22997919
[TBL] [Abstract][Full Text] [Related]
25. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
Singh AK
J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
[No Abstract] [Full Text] [Related]
26. Conversion of darbepoetin to low doses of CERA maintains hemoglobin levels in non-dialysis chronic kidney disease patients.
Minutolo R; Zamboli P; Chiodini P; Mascia S; Vitiello S; Stanzione G; Bertino V; Conte G; De Nicola L
Blood Purif; 2010; 30(3):186-94. PubMed ID: 20924174
[TBL] [Abstract][Full Text] [Related]
27. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
Grabe DW
Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
[TBL] [Abstract][Full Text] [Related]
28. Erythropoiesis-stimulating agents in renal medicine.
Locatelli F; Del Vecchio L
Oncologist; 2011; 16 Suppl 3():19-24. PubMed ID: 21930831
[TBL] [Abstract][Full Text] [Related]
29. Darbepoetin use for the treatment of anemia in hemodialysis patients in Saudi Arabia.
Shaheen FA; Akeel N; Alfi A; Harbi A; Tarif N; Souqiyyeh MZ
Saudi J Kidney Dis Transpl; 2006 Sep; 17(3):365-72. PubMed ID: 16970257
[TBL] [Abstract][Full Text] [Related]
30. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
31. Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment.
Kliger AS; Fishbane S; Finkelstein FO
Clin J Am Soc Nephrol; 2012 Feb; 7(2):354-7. PubMed ID: 22266571
[TBL] [Abstract][Full Text] [Related]
32. Time savings associated with C.E.R.A. once monthly: a time-and-motion study in hemodialysis centers in five European countries.
De Cock E; Dellanna F; Khellaf K; Klatko W; Maduell F; Raluy-Callado M; Villa G
J Med Econ; 2013; 16(5):648-56. PubMed ID: 23402559
[TBL] [Abstract][Full Text] [Related]
33. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease.
Joy MS; Candiani C; Vaillancourt BA; Chin H; Hogan SL; Falk RJ
Pharmacotherapy; 2007 May; 27(5):734-44. PubMed ID: 17461709
[TBL] [Abstract][Full Text] [Related]
34. Emerging drugs for treatment of anemia of chronic kidney disease.
Magwood JS; Lebby A; Chen B; Kessler S; Norris L; Bennett CL
Expert Opin Emerg Drugs; 2013 Dec; 18(4):421-9. PubMed ID: 24033253
[TBL] [Abstract][Full Text] [Related]
35. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study.
Kessler M; Martínez-Castelao A; Siamopoulos KC; Villa G; Spinowitz B; Dougherty FC; Beyer U
Hemodial Int; 2010 Apr; 14(2):233-9. PubMed ID: 19888948
[TBL] [Abstract][Full Text] [Related]
36. CERA: third-generation erythropoiesis-stimulating agent.
Topf JM
Expert Opin Pharmacother; 2008 Apr; 9(5):839-49. PubMed ID: 18345959
[TBL] [Abstract][Full Text] [Related]
37. Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off?
Schmidt RJ
Expert Opin Pharmacother; 2009 Jun; 10(9):1509-14. PubMed ID: 19505218
[TBL] [Abstract][Full Text] [Related]
38. Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?
Berns JS
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):567-72. PubMed ID: 20601876
[TBL] [Abstract][Full Text] [Related]
39. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
[TBL] [Abstract][Full Text] [Related]
40. Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels.
Hess G; Hill J; Clough J; Hulnick S; Nordyke RJ
Curr Med Res Opin; 2008 Mar; 24(3):815-9. PubMed ID: 18257979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]